Publicaciones científicas

15 Publicaciones científicas disponibles

  • RNU6-1 in circulating exosomes differentiates GBM from non-neoplastic brain lesions and PCNSL but not from brain metastases

    31 de enero de 2020 | Revista: Nuero-Oncology Advances

    Montserrat Puigdelloses  (1, 2, 3) , Marisol González-Huárriz  (1, 2, 4) , Marc García-Moure  (1, 2, 4) , Naiara Martínez-Vélez (1, 2, 4) , Inés Esparragosa Vázquez  (1, 2, 3) , Jordi Bruna  (5) , Beatriz Zandio (6) , Amaia Agirre  (7) , Miguel Marigil  (8) , Gregorio Petrirena  (9) , Jorge M Nuñez-Córdoba  (10, 11) , Sonia Tejada-Solís  (1, 12) , Ricardo Díez-Valle  (1, 12) , Jaime Gállego-Culleré (6) , Eduardo Martínez-Vila  (1, 2, 3) , Ana Patiño-García  (1, 2, 4) , Marta M Alonso  (1, 2, 4) , Jaime Gállego Pérez-Larraya  (1, 2, 3)

    (1) Health Research Institute of Navarra (IDISNA), Pamplona, Spain.
    (2) Program in Solid Tumors, Center for the Applied Medical Research (CIMA), University of Navarra, Pamplona, Spain.
    (3) Department of Neurology, Clínica Universidad de Navarra, Pamplona, Spain.
    (4) Department of Pediatrics, Clínica Universidad de Navarra, Pamplona, Spain.
    (5) Department of Neurology, Hospital de Bellvitge, Barcelona, Spain.
    (6) Department of Neurology, Complejo Hospitalario de Navarra, Pamplona, Spain.
    (7) POLYMAT, University of the Basque Country, San Sebastian, Spain.
    (8) Division of Neurosurgery, Lariboisière University Hospital, Paris, France.
    (9) Service de Neuro-Oncologie, Hôpital de la Timone, Marseille, France.
    (10) Research Support Service, Central Clinical Trials Unit, Clínica Universidad de Navarra, Pamplona, Spain.
    (11) Department of Preventive Medicine and Public Health, Medical School, Universidad de Navarra, Pamplona, Spain.
    (12) Department of Neurosurgery, Clínica Universidad de Navarra, University of Navarra, Pamplona, Spain.


  • The Importance of Gender-Related Anticancer Research on Mitochondrial Regulator Sodium Dichloroacetate in Preclinical Studies In Vivo

    20 de agosto de 2019 | Revista: Cancers

    Stakišaitis D (1,2), Juknevičienė M (3), Damanskienė E (3), Valančiūtė A (3), Balnytė I (3), Alonso MM (4).

    (1) Laboratory of Molecular Oncology, National Cancer Institute, 08660 Vilnius, Lithuania.
    (2) Department of Histology and Embryology, Medical Academy, Lithuanian University of Health Sciences, 44307 Kaunas, Lithuania.
    (3) Department of Histology and Embryology, Medical Academy, Lithuanian University of Health Sciences, 44307 Kaunas, Lithuania.
    (4) Department of Pediatrics, Clínica Universidad de Navarra, University of Navarra, 55 Pamplona, Spain.


  • The oncolytic virus Delta-24-RGD elicits an antitumor effect in pediatric glioma and DIPG mouse models

    28 de mayo de 2019 | Revista: Nature Communications

    Martínez-Vélez N (1,2,3), Garcia-Moure M (1,2,3), Marigil M (1,2,3), González-Huarriz M (1,2,3), Puigdelloses M (1,2,4), Gallego Pérez-Larraya J (1,2,4), Zalacaín M (1,2,3), Marrodán L (1,2,3), Varela-Guruceaga M (1,2,3), Laspidea V (1,2,3), Aristu JJ (1,5), Ramos LI (1,5), Tejada-Solís S (1,6), Díez-Valle R (1,6), Jones C (7,8), Mackay A (7,8), Martínez-Climent JA (1,9), García-Barchino MJ (1,9), Raabe E (10,11), Monje M (12), Becher OJ (13), Junier MP (14), El-Habr EA (14), Chneiweiss H (14), Aldave G (15), Jiang H (16), Fueyo J (16,17), Patiño-García A (1,2,3), Gomez-Manzano C (18), Alonso MM (19,20,21).

    (1) Health Research Institute of Navarra (IDISNA), Pamplona, Navarra, Spain.
    (2) Program of Solid Tumors, Center for the Applied Medical Research (CIMA), University of Navarra, Navarra, Pamplona, Spain.
    (3) Department of Pediatrics, Clínica Universidad de Navarra, Pamplona, Spain.
    (4) Department of Neurology, Clínica Universidad de Navarra, Pamplona, Spain.
    (5) Department of Radiation Oncology, Clínica Universidad de Navarra, Pamplona, Spain.
    (6) Department of Neurosurgery, Clínica Universidad de Navarra, Pamplona, Spain.
    (7) Division of Molecular Pathology, The Institute of Cancer Research, 15 Cotswold Road, Sutton, London, Surrey, SM2 5NG, UK.
    (8) Division of Cancer Therapeutics, The Institute of Cancer Research, 15 Cotswold Road, Sutton, London, Surrey, SM2 5NG, UK.
    (9) Division of Hematopoietic Tumors, Center for the Applied Medical Research (CIMA), University of Navarra, CIBERONC, Pamplona, Pamplona, Navarra, Spain.
    (10) Department of Pathology, The Johns Hopkins University School of Medicine, Baltimore, MD, USA.
    (11) Division of Pediatric Oncology, The Johns Hopkins University School of Medicine, Baltimore, MD, USA.
    (12) Department of Neurology, Stanford University School of Medicine, Stanford, CA, USA.
    (13) Department of Pediatrics, Northwestern University and Division of Pediatric Hematology-Oncology and Stem Cell Transplant, Ann & Robert H. Lurie Children's Hospital, Chicago, IL, USA.
    (14) CNRS UMR8246, Inserm U1130, Neuroscience Paris Seine - IBPS, Sorbonne Universities, Paris, France.
    (15) Division of Pediatric Neurosurgery, Department of Surgery, Texas Children's Hospital, Baylor College of Medicine, Houston, TX, USA.
    (16) Department of NeuroOncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
    (17) Department of Neurosurgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
    (18) Department of NeuroOncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
    (19) Health Research Institute of Navarra (IDISNA), Pamplona, Navarra, Spain.
    (20) Program of Solid Tumors, Center for the Applied Medical Research (CIMA), University of Navarra, Navarra, Pamplona, Spain.
    (21) Department of Pediatrics, Clínica Universidad de Navarra, Pamplona, Spain.


  • Delta-24-RGD combined with radiotherapy exerts a potent antitumor effect in diffuse intrinsic pontine glioma and pediatric high grade glioma models

    29 de abril de 2019 | Revista: Acta Neuropathologica Communications

    Martinez-Velez N (1,2,3), Marigil M (1,2,3,4), García-Moure M (1,2,3), Gonzalez-Huarriz M (1,2,3), Aristu JJ (1,5), Ramos-García LI (5), Tejada S (1,2,6), Díez-Valle R (1,2,6), Patiño-García A (1,2,3), Becher OJ (7), Gomez-Manzano C (8,9), Fueyo J (8,10), Alonso MM (11,12,13).

    (1) The Health Research Institute of Navarra (IDISNA), Pamplona, Navarra, Spain.
    (2) Program in Solid Tumors, Foundation for the Applied Medical Research, Pamplona, Navarra, Spain.
    (3) Department of Pediatrics, Clínica Universidad de Navarra, University of Navarra, CIMA Building, Avd. Pio XII, 55, Pamplona, Spain.
    (4) Division of Neurosurgery, Lariboisière University Hospital, 2 Rue Ambroise Paré, 75475, Paris, cedex 10, France.
    (5) Department of Radiation Oncology, Clínica Universidad de Navarra, University of Navarra, Pamplona, Spain.
    (6) Department of Neurosurgery, Clínica Universidad de Navarra, University of Navarra, Pamplona, Spain.
    (7) Department of Pediatrics, Northwestern University and Division of Pediatric Hematology-Oncology and Stem Cell Transplant, Ann & Robert H. Lurie Children's Hospital, Chicago, IL, USA.
    (8) Department of Genetics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
    (9) Department of NeuroOncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
    (10) Department of Neurosurgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
    (11) The Health Research Institute of Navarra (IDISNA), Pamplona, Navarra, Spain.
    (12) Program in Solid Tumors, Foundation for the Applied Medical Research, Pamplona, Navarra, Spain.
    (13) Department of Pediatrics, Clínica Universidad de Navarra, University of Navarra, CIMA Building, Avd. Pio XII, 55, Pamplona, Spain.